title: [Expression of RASSF1A and RASSF1C transcripts in human primary ovarian cancers].
abstract: OBJECTIVE
  To investigate the expression of two major alternative transcripts of RASSF1 gene (RASSF1A and RASSF1C) in human primary ovarian cancers and their biological implication as a new tumor suppressor gene.
  
  
  METHODS
  Reverse transcription-polymerase chain reaction (RT-PCR) and laser capture microdissection (LCM) were used to determine mRNA expression of the two major alternative transcripts of RASSF1 gene (RASSF1A and RASSF1C) in 3 ovarian cancer cell lines and 80 cases of primary ovarian cancers.
  
  
  RESULTS
  RASSF1A mRNA was undetectable in SK-OV-3 cell line. Expression of RASSF1A and RASSF1C in 80 primary ovarian cancers were 40.0% (32/80) and 91.3% (73/80) respectively. RASSF1A mRNA expression was detectable more frequently in stage I and II (71.4%, 10/14; 75.0%, 9/12) than in stage III and IV ovarian cancers (26.7%, 12/45; 14.1%, 1/9) (P < 0.05). The expression level was also higher in well and moderately differentiated tumor groups (58.6%, 17/29; 50.0%, 10/20) than in poorly differentiated tumor group (16.1%, 5/31) (P < 0.05).
  
  
  CONCLUSIONS
  There is a preferential loss of RASSF1A expression in human ovarian cancers and its expression is correlated with the tumor stage and the degree of histological differentiation which, as a tumor suppressor gene, might play an important role in the tumorigenesis of human primary ovarian cancer.
authors.affiliation: Department of Obstetric and Gynecology, The Second Affiliated Hospital, China Medical University, Shenyang 110004, China. malincn2000@yahoo.com.cn
authors.forename: Lin
authors.initials: L
authors.lastname: Ma
authors.forename: Jun-hang
authors.initials: JH
authors.lastname: Zhang
authors.forename: Fu-rong
authors.initials: FR
authors.lastname: Liu
authors.forename: Xue
authors.initials: X
authors.lastname: Zhang
mesh_terms: D018269:Carcinoma, Endometrioid / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D018282:Cystadenocarcinoma, Mucinous / Q000378:metabolism / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis* / Q000235:genetics
chemical_list: C411762:RASSF1 protein, human; D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins